HUTCHMED (China) Limited (HCM)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

HUTCHMED (China) Limited (HCM) is down 13.6% since the beginning of the year. At $12 per share, HCM is trading 40.9% below its 52-week high of $20. Investors who bought $1,000 worth of HCM shares 5 years ago would now be looking at an investment worth $380.

HUTCHMED (China) Limited (HCM) has returned -13.58% so far this year and -15.29% over the past 12 months. Over the last ten years, HCM has returned -1.54% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Mar 17, 2016, HCM's average daily return is +0.06%, while the average monthly return is +0.92%. At this rate, an investment would double in approximately 6.3 years.

Historically, 48% of months were positive and 52% were negative. The best month was Mar 2017 with a return of +56.6%, while the worst month was Dec 2018 at -33.0%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 4 months.

On a daily basis, HCM closed higher 50% of trading days. The best single day was Mar 15, 2017 with a return of +28.4%, while the worst single day was Jun 28, 2019 at -27.2%.

HUTCHMED (China) Limited has an annualized alpha of 1.35%, beta of 1.01, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since March 18, 2016.

• This stock participated in 77.33% of S&P 500 Index downside but only 29.24% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

HCM ranks 25 for risk / return — below 25% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for HUTCHMED (China) Limited (HCM) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the HUTCHMED (China) Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the HUTCHMED (China) Limited was 82.18%, occurring on Oct 25, 2022. The portfolio has not yet recovered.

The current HUTCHMED (China) Limited drawdown is 73.17%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of HUTCHMED (China) Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how HUTCHMED (China) Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.